Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Biologics. 2014 Apr 16;8:155-67. doi: 10.2147/BTT.S27578. eCollection 2014.

Abstract

Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.

Keywords: Retacrit®; biosimilar; chronic kidney disease; epoetin alfa; erythropoiesis; renal anemia.

Publication types

  • Review